Table 1 Respondent characteristics
Characteristics | Overall (n = 205) | Sub-group by number of MS patients under care | P value‡ | ||
|---|---|---|---|---|---|
Group 1: 1–3 patients (n = 69) | Group 2: 4–9 patients (n = 58) | Group 3: ≥10 patients (n = 78) | |||
Age, n (%) | |||||
20s | 4 (2.0) | 3 (4.3) | 0 (0.0) | 1 (1.3) | 0.197 |
30s | 65 (31.7) | 25 (36.2) | 17 (29.3) | 23 (29.5) | |
40s | 80 (39.0) | 25 (36.2) | 24 (41.4) | 31 (39.7) | |
50s | 45 (22.0) | 13 (18.8) | 13 (22.4) | 19 (24.4) | |
≥ 60s | 11 (5.4) | 3 (4.3) | 4 (6.9) | 4 (5.1) | |
Number of MS patients under care, mean ± SD, (min–max) | 8.78 ± 8.92 (1–50) | 2.35 ± 0.78 | 5.14 ± 1.03 | 17.17 ± 9.54 | < 0.001* |
Approximate percentages of patients with MS under care, mean ± SD, (min–max) | 6.56 ± 7.64 (1–60) | 3.14 ± 2.63 (1–10) | 5.41 ± 7.41 (1–50) | 10.44 ± 9.01 (1–60) | < 0.001* |
Years of post-residency treatment experience with MS, n (%) | |||||
< 3 years | 8 (3.9) | 4 (5.8) | 2 (3.4) | 2 (2.6) | 0.009 |
3–5 years | 16 (7.8) | 9 (13.0) | 2 (3.4) | 5 (6.4) | |
6–10 years | 37 (18.0) | 14 (20.3) | 12 (20.7) | 11 (14.1) | |
11–15 years | 51 (24.9) | 18 (26.1) | 14 (24.1) | 19 (24.4) | |
16–20 years | 40 (19.5) | 11 (15.9) | 14 (24.1) | 15 (19.2) | |
> 20 years | 53 (25.9) | 13 (18.8) | 14 (24.1) | 26 (33.3) | |
Affiliation, n (%) | |||||
University hospitals | 60 (29.3) | 19 (27.5) | 8 (13.8) | 33 (42.3) | 0.019 |
National/public hospitals | 58 (28.3) | 18 (26.1) | 20 (34.5) | 20 (25.6) | |
Hospitals in general | 79 (38.5) | 28 (40.6) | 27 (46.6) | 24 (30.8) | |
Private practice | 8 (3.9) | 4 (5.8) | 3 (5.2) | 1 (1.3) | |
Membership in professional association†, n (%) | |||||
Japanese Society of Neurology | 204 (99.5) | 68 (98.6) | 58 (100.0) | 78 (100.0) | 0.217 |
Japanese Society for Neuroimmunology | 36 (17.6) | 10 (14.5) | 7 (12.1) | 19 (24.4) | 0.108 |
Japanese Society of Neurological Therapeutics | 87 (42.4) | 18 (26.1) | 27 (46.6) | 42 (53.8) | 0.001 |
DMDs that had been prescribed in practice†, n (%) | |||||
SC IFNβ-1b | 199 (97.1) | 63 (91.3) | 58 (100.0) | 78 (100.0) | 0.002 |
IM IFNβ-1a | 180 (87.8) | 60 (87.0) | 47 (81.0) | 73 (93.6) | 0.199 |
Fingolimod | 171 (83.4) | 50 (72.5) | 47 (81.0) | 74 (94.9) | < 0.001 |
Natalizumab | 32 (15.6) | 8 (11.6) | 3 (5.2) | 21 (26.9) | 0.009 |
Glatiramer acetate | 36 (17.6) | 13 (18.8) | 6 (10.3) | 17 (21.8) | 0.600 |
Other | 5 (2.4) | 2 (2.9) | 1 (1.7) | 2 (2.6) | 0.907 |